Identification of an antimalarial synthetic trioxolane drug development candidate

Author(s): Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, et al.


The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. Available evidence suggests that artemisinin and related peroxidic antimalarial drugs exert their parasiticidal activity subsequent to reductive activation by haem, released as a result of haemoglobin digestion by the malaria-causing parasite. This irreversible redox reaction produces carbon-centred free radicals, leading to alkylation of haem and proteins (enzymes), one of which--the sarcoplasmic-endoplasmic reticulum ATPase PfATP6 (ref. 7)--may be critical to parasite survival. Notably, there is no evidence of drug resistance to any member of the artemisinin family of drugs. The chemotherapy of malaria has benefited greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have good therapeutic indices and provide for successful treatment outcomes. However, as a drug class, the artemisinins suffer from chemical (semi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pharmacokinetics) and treatment (non-compliance with long treatment regimens and recrudescence) issues that limit their therapeutic potential. Here we describe how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.

Similar Articles

Medicinal plants in therapy

Author(s): Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z

Burger's medicinal chemistry and drug discovery

Author(s): James F, Kerwin Jr.

Antimalarial drug resistance

Author(s): White NJ

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial

Author(s): Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group

Artesunate versus quinine for severe falciparum malaria

Author(s): Woodrow CJ, Planche T, Krishna S

Artemisinins: activities and actions

Author(s): Haynes RK, Krishna S

Artemisone--a highly active antimalarial drug of the artemisinin class

Author(s): Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann HD, et al.

A single amino acid residue can determine the sensitivity of SERCAs to artemisinins

Author(s): Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, et al.

Synthetic studies towards halichondrins: synthesis of the C

Author(s): Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, et al.

Enabling high-throughput discovery

Author(s): Vaschetto M, Weissbrod T, Bodle D, Güner O